Name | Ranolazine HCl |
Synonyms | Ranolazine2Hcl Ranolazine HCl RANOLAZINE HCL Ranolazine DiHCI RANOLAZINE DI HCL Ranolazine and salt Ranolazine hydrochloride Ranolazine Dihydrochloride RANOLAZINE DIHYDROCHLORIDE (±)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide N-(2,6-Dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)-propyl)piperazin-1-yl)acetamide di N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide dihydrochloride n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide dihydrochloride |
CAS | 95635-56-6 |
InChI | InChI=1/C24H33N3O4.2ClH/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3;;/h4-10,20,28H,11-17H2,1-3H3,(H,25,29);2*1H |
Molecular Formula | C24H35Cl2N3O4 |
Molar Mass | 500.46 |
Melting Point | 222-229.5°C(lit.) |
Boling Point | 624.1°C at 760 mmHg |
Flash Point | 331.2°C |
Solubility | Soluble in DMSO (100 mg/ml at 25° C), water (100 mg/ml at 25° C), and ethanol (<1 m |
Vapor Presure | 1.94E-16mmHg at 25°C |
Appearance | solid |
Color | off-white |
Merck | 14,8111 |
Storage Condition | Desiccate at RT |
Stability | Hygroscopic |
MDL | MFCD03788770 |
Use | A novel metabolic modulator. |
In vitro study | In cardiomyocytes, Ranolazine selectively inhibits anaphase I (sodium), reduces sodium-dependent calcium overload, and attenuates ventricular repolarization and contraction, this is associated with abnormalities in ischemia/reperfusion injury and heart failure. In dog left ventricular myocytes, Ranolazine shortened the action potential duration (APD) of myocytes stimulated at 0.5Hz or 0.25Hz in a concentration-dependent manner and reversibly. Ranolazine at 5 mM and 10 mM reversibly shortened the duration of Twitch contractions (TC) and canceled the aftercontractions. Ranolazine was found to bind more to the inactive state of sodium channels. |
In vivo study | In the working heart, Ranolazine(10 mM) significantly increased glucose oxidation by 1.5 to 3 times, where the contribution of glucoseto's overall ATP production was low (low calcium, high FA, insulin), high (high calcium, low FA), or intermediate. In the Langendorff heart (high calcium, low FA;15 mL/min), Ranolazine likewise increased glucose oxidation. Ranolazine similarly increased glucose oxidation as the flow rate decreased to 7 ml/min, 3 ml/min, and 0.5 mL/min. Ranolazine significantly improved functional output, which was associated with a significant increase in glucoseoxidation, reversed the increase in fatty acid oxidation in the control group, and significantly increased glycolysis in the reperfuse dischemic working heart. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |
RTECS | TK7845370 |
HS Code | 29335990 |